Home › Lupus › New York › Rochester
Lupus clinical trials in Rochester, NY
4 studies for Lupus are looking for participants at sites in and around Rochester (within about 30 miles). Open a study to see who can join and how to contact the study team.
RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
RecruitingPhase 1/2
- University of Rochester, Rochester
A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases
RecruitingPhase 2
- University of Rochester Medical Center, Rochester
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study With an Open-Label Extension Evaluating the Efficacy and Safety of VENT-03 in Adult Participants With Active Cutaneous Lupus Erythematosus With or Without Systemic Lupus Erythematosus
RecruitingPhase 2
- Investigative Site, Fairport · 10 mi away
A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus
RecruitingPhase 1
- University of Rochester Medical Center, Rochester
About Lupus
Lupus is an autoimmune disease that causes your immune system to attack your healthy tissues and cells. This can cause damage to many parts of your body.
More about Lupus on MedlinePlus
Lupus trials in other cities
- New York City, NY18 studies
- Houston, TX12 studies
- Durham, NC12 studies
- Washington, DC10 studies
- Miami, FL10 studies
- Philadelphia, PA9 studies
- Tampa, FL9 studies
- Santa Monica, CA8 studies
- Chicago, IL8 studies
- Boston, MA8 studies
- Los Angeles, CA8 studies
- Clearwater, FL8 studies
Other studies in Rochester
- Acute Myeloid Leukemia16 studies
- Cancer (all types)15 studies
- Breast Cancer15 studies
- Lung Cancer15 studies
- Obesity14 studies
- Overweight13 studies
- Non-Small Cell Lung Cancer13 studies
- Prostate Cancer10 studies
- Metastatic Cancer8 studies
- Multiple Myeloma8 studies
- Pancreatic Cancer7 studies
- Bladder Cancer7 studies
From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.